Ticlopidine-induced cholestatic hepatitis

Annals of Pharmacotherapy

Volumn 37, Issue 3, 2003, Pages 371-375

  Skurnik, Yair D ^a   Tcherniak, Alexandra ^a   Edlan, Karl ^a   Sthoeger, Zev ^a,b   Martínez, Mirza D ^c   Larouche, Marie ^c  

^a KAPLAN MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY   (Israel)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; ATENOLOL; BEZAFIBRATE; CLOPIDOGREL; CORTICOSTEROID; FAMOTIDINE; FLUINDOSTATIN; ISOSORBIDE MONONITRATE; METFORMIN; SIMVASTATIN; TICLOPIDINE; URSODEOXYCHOLIC ACID;

AGED; ARTICLE; BLOOD CELL COUNT; CASE REPORT; CHOLESTATIC HEPATITIS; CORONARY ARTERY DILATATION; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; LYMPHOCYTE ACTIVATION; MALE; PRIORITY JOURNAL; REMISSION; SIDE EFFECT;

EID: 0037371035     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A406     Document Type: Article

References (26)

1. Patrono C, Coller CB, Dalen JE, Fuster V, Gent M, Harker LA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 1998;114(suppl):470s-488s.
2. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667-72.
3. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-20.
4. Hass WK, Easton JD, Adams HP, Pryse-Phillips W, Molony BA, Anderson S, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study (TASS) Group. N Engl J Med 1989;321:501-7.
5. Berger PB, Bell MR, Grill DE, Melby S, Holmes DR. Frequency of adverse clinical events in the 12 months following successful intracoronary stent placement in patients treated with aspirin and ticlopidine (without warfarin). Am J Cardiol 1998;81:713-18.
6. Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicenter Study. J Intern Med 1990;227:301-8.
7. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell' Angina Instabile Group. Circulation 1990;82:17-26.
8. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
9. Sthoeger ZM, Chiorazzi N, Lahita RG. Regulation of the immune response by sex hormones. I. In vitro effects of estradiol and testosterone on pokeweed mitogen-induced human B cell differentiation. J Immunol 1988;141:91-8.
10. Dayan M, Segal R, Sthoeger Z, Waisman A, Brosh N, Elkayam U, et al. Immune response of SLE patients to peptides based on the complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. J Clin Immunol 2000;20:187-90.
11. Iqbal M, Goenke P, Young MF, Eapen T, Borthwick TR. Ticlopidine-induced cholestatic hepatitis. Report of three cases and review of the literature. Dig Dis Sci 1998;43:2223-6.
12. Grieco A, Vecchio FM, Greco AV, Gasbarrini G. Cholestatic hepatitis due to ticlopidine: clinical and histological recovery after drug withdrawal. Case report and review of the literature. Eur J Gastroenterol Hepatol 1998;10:713-5.
13. Kubin CJ, Sherman O, Hussain KB, Feinman L. Delayed-onset ticlopidine induced cholestatic jaundice. Pharmacotherapy 1999;19:1006-10.
14. Klepser TB, Jogerst GJ. Ticlopidine-induced elevation of liver enzymes. Pharmacotherapy 1997;17:819-21.
15. Meyer MI, Kuhn M, Buhler H, Bertschiniger P. Ticlopidine-induced cholestasis. Schweiz Med Wochenschr 1999;129:1405-9.
16. Wegmann C, Munzenmaier R, Dormann AJ, Huchzermeyer H. Ticlopidine induced acute cholestatic hepatitis. Dtsch Med Wochenschr 1998;123:146-50.
17. Amaro P, Nunes A, Macoas F, Ministro P, Baranda J, Cipriano A, et al. Ticlopidine induced prolonged cholestasis: a case report. Eur J Gastroenterol Hepatol 1999;11:673-6.
18. Ceylan C, Kirimli O, Akarsu M, Under B, Guneri S. Early ticlopidine-induced hepatic dysfunction, dermatitis and irreversible aplastic anemia after coronary artery stenting. Am J Hematol 1998;59:260-4.
19. Zeolla MM, Carson JJ. Successful use of clopidogrel for cerebrovascular accident in a patient with suspected ticlopidine-induced hepatotoxicity. Ann Pharmacother 1999;33:939-41.
20. Martinez Perez-Balsa A, De Arce A, Castiella A, Lopez P, Ruibal M, Ruiz-Martinez J, et al. Hepatotoxicity due to ticlopidine. Ann Pharmacother 1998;32:1250-1.
21. Sossai P, Corte GD, Marenzi R. Liver injury with the use of ticlopidine. Ann Pharmacother 1998;32:1370-1.
22. Torrano-Larrion F. Cholestatic hepatitis from ticlopidine. Aten Primaria 1999;24:115.
23. Sanchez-Bisono JR, Gomez-Moli J, Escudero-Canto M. Probable ticlopidine-induced severe aplastic anemia and cholestatic hepatitis. Hematologica 1997;82:639.
24. San-Juan-Portugal F, Jimenez-Saez J, Naya-Manchado J, Fuentes-Solsona F. Cholestatic hepatitis due to ticlopidine: a report of a new case. Ann Med Interna 1997;14:540-1.
25. Bruguera M. [Cholestatic hepatitis associated with ticlopidine.] Spanish. Gastroenterol Hepatol 1997;20:163-4.
26. Goland S, Malnick SDH, Gratz R, Feldenberg E, Geltner D, Sthoeger ZM. Severe cholestatic hepatitis following cloxacillin treatment. Postgrad Med J 1998;74:59-60.